A Pilot Trial of Disposable Nitrous Oxide Canisters in Providing Pain Control During Burn Dressing Changes

Sponsor
University of Manitoba (Other)
Overall Status
Recruiting
CT.gov ID
NCT03695887
Collaborator
(none)
30
1
2
50
0.6

Study Details

Study Description

Brief Summary

Improvements in burn care have resulted in increased survival. Despite these improved outcomes one of the leading challenges of burn care remains providing adequate analgesia during routine wound care and dressing changes. The traditional use of narcotics is challenging as the therapeutic window between analgesia and suppression of breathing becomes narrow with the intense pain and high doses of narcotics needed for dressing changes.

Condition or Disease Intervention/Treatment Phase
  • Drug: Nitrous Oxide Inhalant Product
  • Drug: Placebo
Early Phase 1

Detailed Description

The normal challenges of using narcotics are increased in burn patients, who have significantly altered metabolism. Unfortunately, the use of regular general anesthesia or conscious sedation is not a viable option due to the resources required, and as the hypermetabolism of burn injury would result in compromised wound healing with repeated periods of without eating related halting of nutritional intake. This has led to the use of a number of adjuncts ranging from nonmedical (virtual reality, mindfulness, hypnosis etc.) to medication (ketamine, anxiolytics etc.). Historically Nitrous oxide has been used in similar settings where severe procedural pain is of relatively shorter duration, such as tooth extraction, labor or minor surgical procedures. Nitrous oxide is a rapidly acting analgesic that takes effect seconds after inhalation, and lasts minutes. While a randomized trial of Nitrous oxide in burn care has been proposed, the only published information currently available is in a Chinese medical journal.

To address this a gap in knowledge, a pilot Randomized Controlled trial is proposed to evaluate if Nitrous Oxide in the form of limited dose inhaler canisters can be used to improve pain control during burn dressing changes compared to placebo canisters.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Intervention Model Description:
Randomized to receive either active study article or inactive comparator then crossed over to other treatment arm on next dressing change.Randomized to receive either active study article or inactive comparator then crossed over to other treatment arm on next dressing change.
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
A Pilot Randomized Controlled Crossover Trial of the Effectiveness of Disposable Nitrous Oxide Canisters in Providing Improved Pain Control During Burn Dressing Changes.
Actual Study Start Date :
Oct 1, 2019
Anticipated Primary Completion Date :
Dec 1, 2023
Anticipated Study Completion Date :
Dec 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Nitrous Oxide Inhalant Product

Nitrous oxide

Drug: Nitrous Oxide Inhalant Product
Nitrous Oxide Inhalant Product

Placebo Comparator: Placebo

placebo comparator

Drug: Placebo
Inactive comparator

Outcome Measures

Primary Outcome Measures

  1. Burn Specific Pain Anxiety Scale [1 hour before dressing change]

    The experience of the dressing change for the patient will also be assessed using the Burn specific pain and anxiety scale which consists of: Worry about wound-healing Fear of procedural pain Fear of losing control because of pain Fear of pain during dressing change Pain severity Keyed up because of enduring pain Concern about wound healing Preoccupied with pain Tension during dressing change Responses for each item are on a visual analogue scale ranging from "least" to "most". The response is normalized to a value between 0 and 1, representing the location selected on the line, divided by the total length of the line. The responses will be used to examine a possible relationship procedural and non procedural pain between the nurse and the patient.

  2. Burn Specific Pain Anxiety Scale [during dressing change]

    The experience of the dressing change for the patient will also be assessed using the Burn specific pain and anxiety scale which consists of: Worry about wound-healing Fear of procedural pain Fear of losing control because of pain Fear of pain during dressing change Pain severity Keyed up because of enduring pain Concern about wound healing Preoccupied with pain Tension during dressing change Responses for each item are on a visual analogue scale ranging from "least" to "most". The response is normalized to a value between 0 and 1, representing the location selected on the line, divided by the total length of the line. The responses will be used to examine a possible relationship procedural and non procedural pain between the nurse and the patient.

  3. Burn Specific Pain Anxiety Scale [1 hour after dressing change]

    The experience of the dressing change for the patient will also be assessed using the Burn specific pain and anxiety scale which consists of: Worry about wound-healing Fear of procedural pain Fear of losing control because of pain Fear of pain during dressing change Pain severity Keyed up because of enduring pain Concern about wound healing Preoccupied with pain Tension during dressing change Responses for each item are on a visual analogue scale ranging from "least" to "most". The response is normalized to a value between 0 and 1, representing the location selected on the line, divided by the total length of the line. The responses will be used to examine a possible relationship procedural and non procedural pain between the nurse and the patient.

  4. Visual Analogue Scale for pain [1 hour before dressing change]

    The items are scored on a 100 mm visual analog line with two reference points given values of 0 ("No pain") and 100 ("worst possible pain").

  5. Visual Analogue Scale for pain [during dressing change]

    The items are scored on a 100 mm visual analog line with two reference points given values of 0 ("No pain") and 100 ("worst possible pain").

  6. Visual Analogue Scale for pain [1 hour after dressing change]

    The items are scored on a 100 mm visual analog line with two reference points given values of 0 ("No pain") and 100 ("worst possible pain").

  7. Visual Analogue Scale for anxiety [1 hour before dressing change]

    The items are scored on a 100 mm visual analog line with two reference points given values of 0 ("no anxiety") and 100 ("worst possible anxiety").

  8. Visual Analogue Scale for anxiety [during dressing change]

    The items are scored on a 100 mm visual analog line with two reference points given values of 0 ("no anxiety") and 100 ("worst possible anxiety").

  9. Visual Analogue Scale for anxiety [1 hour after dressing change]

    The items are scored on a 100 mm visual analog line with two reference points given values of 0 ("no anxiety") and 100 ("worst possible anxiety").

Secondary Outcome Measures

  1. Anxiolytic given [1 hour before dressing change]

    The amount of anxiolytic given one hour prior to the dressing change.

  2. Anxiolytic given [during dressing change]

    The amount of anxiolytic given during the dressing change.

  3. Anxiolytic given [1 hour after dressing change]

    The amount of anxiolytic given one hour after the dressing change.

Other Outcome Measures

  1. Systolic blood pressure [5 minute mark during burn dressing change]

    After administration of inhaled nitrous oxide, systolic blood pressure will be measured.

  2. Systolic blood pressure [10 minute mark during burn dressing change]

    After administration of inhaled nitrous oxide, systolic blood pressure will be measured.

  3. Systolic blood pressure [15 minute mark during burn dressing change]

    After administration of inhaled nitrous oxide, systolic blood pressure will be measured.

  4. Systolic blood pressure [20 minute mark during burn dressing change]

    After administration of inhaled nitrous oxide, systolic blood pressure will be measured.

  5. Diastolic blood pressure [5 minute mark during burn dressing change]

    After administration of inhaled nitrous oxide, Diastolic blood pressure will be measured.

  6. Diastolic blood pressure [10 minute mark during burn dressing change]

    After administration of inhaled nitrous oxide, Diastolic blood pressure will be measured.

  7. Diastolic blood pressure [15 minute mark during burn dressing change]

    After administration of inhaled nitrous oxide, Diastolic blood pressure will be measured.

  8. Diastolic blood pressure [20 minute mark during burn dressing change]

    After administration of inhaled nitrous oxide, Diastolic blood pressure will be measured.

  9. Mean arterial pressure [5 minute mark during burn dressing change]

    After administration of inhaled nitrous oxide, mean arterial pressure (mmHg) will be measured.

  10. Mean arterial pressure [10 minute mark during burn dressing change]

    After administration of inhaled nitrous oxide, mean arterial pressure (mmHg) will be measured.

  11. Mean arterial pressure [15 minute mark during burn dressing change]

    After administration of inhaled nitrous oxide, mean arterial pressure (mmHg) will be measured.

  12. Mean arterial pressure [20 minute mark during burn dressing change]

    After administration of inhaled nitrous oxide, mean arterial pressure (mmHg) will be measured.

  13. Heart rate [5 minute mark during burn dressing change]

    After administration of inhaled nitrous oxide, heart rate will be measured.

  14. Heart rate [10 minute mark during burn dressing change]

    After administration of inhaled nitrous oxide, heart rate will be measured.

  15. Heart rate [15 minute mark during burn dressing change]

    After administration of inhaled nitrous oxide, heart rate will be measured.

  16. Heart rate [20 minute mark during burn dressing change]

    After administration of inhaled nitrous oxide, heart rate will be measured.

  17. Oxygen saturation [5 minute mark during burn dressing change]

    After administration of inhaled nitrous oxide, oxygen saturation will be measured.

  18. Oxygen saturation [10 minute mark during burn dressing change]

    After administration of inhaled nitrous oxide, oxygen saturation will be measured.

  19. Oxygen saturation [15 minute mark during burn dressing change]

    After administration of inhaled nitrous oxide, oxygen saturation will be measured.

  20. Oxygen saturation [20 minute mark during burn dressing change]

    After administration of inhaled nitrous oxide, oxygen saturation will be measured.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No

Inclusion criteria

  • adult burn patients admitted to the Health Sciences Centre

  • total body surface area burned of 5-20%

Exclusion criteria

  • admitted to intensive care unit

  • unable to participate in the measurement outcomes (sedated, cognitively impaired, unable to understand English or visually impaired)

  • medical condition that precludes using nitrous oxide (respiratory disease and significant cardiovascular disease 5).

  • pregnant

  • physically unable to hold the canister

  • <90% SaO2 on room air

  • face burn

  • pre-injury narcotics (relative exclusion)

  • use of IV ketamine

  • pre-existing lung injury

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Manitoba Winnipeg Manitoba Canada R3A 1R9

Sponsors and Collaborators

  • University of Manitoba

Investigators

  • Principal Investigator: Sarvesh Logsetty, University of Manitoba

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Dr. Sarvesh Logsetty, Professor, University of Manitoba
ClinicalTrials.gov Identifier:
NCT03695887
Other Study ID Numbers:
  • nitrousoxide
First Posted:
Oct 4, 2018
Last Update Posted:
May 17, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Dr. Sarvesh Logsetty, Professor, University of Manitoba
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 17, 2022